Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Roivant Sciences Ltd. (RSL)	Series A  preferred stock	Common stock	Additional paid-in capital	Additional paid-in capital Roivant Sciences Ltd. (RSL)	Accumulated other comprehensive income (loss)	Accumulated deficit
Beginning balance (in shares) at Mar. 31, 2021			10,000	97,971,243
Beginning balance at Mar. 31, 2021	$ 391,480			$ 10	$ 590,425		$ (298)	$ (198,657)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted stock units vested and settled (in shares)				6,352
Capital contribution – stock-based compensation	41				41
Capital contribution – expenses allocated from Roivant Sciences Ltd.		$ 91				$ 91
Stock-based compensation	3,820				3,820
Foreign currency translation adjustments	571						571
Net loss	(30,471)							(30,471)
Ending balance (in shares) at Jun. 30, 2021			10,000	97,977,595
Ending balance at Jun. 30, 2021	365,532			$ 10	594,377		273	(229,128)
Beginning balance (in shares) at Mar. 31, 2022			10,000	116,482,899
Beginning balance at Mar. 31, 2022	469,825			$ 12	824,796		404	(355,387)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised and restricted stock units vested and settled (in shares)				41,259
Stock options exercised and restricted stock units vested and settled	21				21
Capital contribution – stock-based compensation	132				132
Stock-based compensation	7,555				7,555
Foreign currency translation adjustments	(667)						(667)
Net loss	(40,373)							(40,373)
Ending balance (in shares) at Jun. 30, 2022			10,000	116,524,158
Ending balance at Jun. 30, 2022	$ 436,493			$ 12	$ 832,504		$ (263)	$ (395,760)